Nisa Investment Advisors LLC grew its holdings in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) by 1,021.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,440 shares of the biotechnology company’s stock after buying an additional 10,420 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Arrowhead Pharmaceuticals were worth $726,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Municipal Employees Retirement System of Michigan lifted its position in shares of Arrowhead Pharmaceuticals by 1.3% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 28,560 shares of the biotechnology company’s stock valued at $805,000 after buying an additional 380 shares in the last quarter. United Services Automobile Association raised its position in Arrowhead Pharmaceuticals by 2.6% during the second quarter. United Services Automobile Association now owns 20,515 shares of the biotechnology company’s stock worth $544,000 after acquiring an additional 522 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Arrowhead Pharmaceuticals by 10.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,701 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 531 shares in the last quarter. Comerica Bank lifted its holdings in Arrowhead Pharmaceuticals by 0.7% during the third quarter. Comerica Bank now owns 89,234 shares of the biotechnology company’s stock valued at $3,291,000 after purchasing an additional 627 shares in the last quarter. Finally, Mason Street Advisors LLC grew its position in shares of Arrowhead Pharmaceuticals by 2.2% in the third quarter. Mason Street Advisors LLC now owns 32,360 shares of the biotechnology company’s stock valued at $912,000 after purchasing an additional 711 shares during the period. Institutional investors and hedge funds own 69.81% of the company’s stock.
Shares of NASDAQ ARWR opened at $44.01 on Tuesday. The firm has a 50-day simple moving average of $60.16 and a 200-day simple moving average of $42.61. The stock has a market capitalization of $4.27 billion, a price-to-earnings ratio of 63.78 and a beta of 1.97. Arrowhead Pharmaceuticals Inc has a 52 week low of $12.72 and a 52 week high of $73.72.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Monday, November 25th. The biotechnology company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.03). The business had revenue of $43.29 million for the quarter, compared to analyst estimates of $36.97 million. Arrowhead Pharmaceuticals had a return on equity of 32.30% and a net margin of 40.27%. Equities research analysts expect that Arrowhead Pharmaceuticals Inc will post -0.16 earnings per share for the current fiscal year.
A number of analysts have recently commented on the stock. BidaskClub cut shares of Arrowhead Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. Oppenheimer assumed coverage on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. They issued a “hold” rating on the stock. Svb Leerink assumed coverage on Arrowhead Pharmaceuticals in a report on Tuesday, January 21st. They issued an “underperform” rating and a $32.00 price objective on the stock. S&P Equity Research reiterated a “buy” rating on shares of Arrowhead Pharmaceuticals in a report on Tuesday, November 26th. Finally, Leerink Swann started coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, January 21st. They set an “underperform” rating and a $32.00 price objective for the company. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $61.14.
In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 37,967 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $69.15, for a total value of $2,625,418.05. Following the completion of the sale, the chief executive officer now directly owns 2,116,160 shares in the company, valued at approximately $146,332,464. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, General Counsel Patrick O’brien sold 14,625 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $60.12, for a total value of $879,255.00. Following the completion of the sale, the general counsel now owns 267,406 shares of the company’s stock, valued at $16,076,448.72. The disclosure for this sale can be found here. Insiders sold a total of 286,402 shares of company stock worth $17,138,919 over the last three months. Corporate insiders own 4.80% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Featured Story: FTSE 100 Index
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.